• Skip to primary navigation
  • Skip to main content
  • FortiVac
  • Uses
  • Publications & Patents
Multimeric Biotherapeutics

Multimeric Biotherapeutics

FortiVac Vaccine Platform Technology

  • News & Events
  • About Us
  • Contact

Multimeric Biotherapeutics to Present at Keystone Symposium on Innovative Vaccine Approaches

June 17, 2021 | Events

SAN DIEGO, CA , June 17, 2021 – Multimeric Biotherapeutics, Inc., a biotechnology company developing vaccines against cancer and infectious diseases, announced today that it has been accepted to present at the Keystone Symposium on Innovative Vaccine Approaches. The meeting will be held as a virtual web conference scheduled June 28-30, 2021.

Richard S. Kornbluth, MD, PhD, President & Chief Scientific Officer will present an overview of Multimeric’s new vaccine platform (FortiVacTM) that elicits very strong CD8+ T cell responses against the chosen antigen. The Company will present a poster and give a short talk about the technology.

A link to the poster can be found here.

About Multimeric

Multimeric Biotherapeutics, Inc. is a biotechnology company developing vaccines against infectious diseases and cancer using FortiVac, a novel patented vaccine platform. The technology uses CD40 ligand (CD40L) as a key immune activator for generating robust CD8+ T cell responses. The Company is currently developing FortiVac for cancer vaccine indications.

Multimeric Biotherapeutics, Inc. | 5580 La Jolla Blvd Ste 76, La Jolla, CA 92037

2025 © Multimeric Biotherapeutics, Inc. All rights reserved.